TABLE 2.
Lifetime discounted cost‐effectiveness results, by population subgroup
| Scenario | Outcome | Control | Dapagliflozin | Difference |
|---|---|---|---|---|
| Overall | Life‐years | 13.53 | 13.54 | 0.00 |
| QALYs | 10.43 | 10.48 | 0.06 | |
| Costs | £39 451 | £36 899 | −£2552 | |
| NMB | £169 071 | £172 730 | £3660 | |
| ICER | Dominant | |||
| MRF | Life‐years | 13.81 | 13.81 | 0.00 |
| QALYs | 10.53 | 10.60 | 0.07 | |
| Costs | £30 837 | £29 086 | −£1752 | |
| NMB | £179 776 | £183 002 | £3226 | |
| ICER | Dominant | |||
| eCVD | Life‐years | 12.63 | 12.63 | 0.00 |
| QALYs | 8.96 | 9.06 | 0.09 | |
| Costs | £46 293 | £43 462 | −£2831 | |
| NMB | £132 946 | £137 641 | £4694 | |
| ICER | Dominant | |||
| No prior HF | Life‐years | 13.69 | 13.70 | 0.00 |
| QALYs | 10.38 | 10.45 | 0.07 | |
| Costs | £31 505 | £29 486 | −£2018 | |
| NMB | £176 105 | £179 490 | £3385 | |
| ICER | Dominant | |||
| Prior HF | Life‐years | 10.80 | 10.81 | 0.00 |
| QALYs | 6.70 | 6.80 | 0.11 | |
| Costs | £61 568 | £57 419 | −£4150 | |
| NMB | £72 420 | £78 486 | £6067 | |
| ICER | Dominant |
Abbreviations: CVOT, cardiovascular outcome trial; eCVD, established cardiovascular disease; HF, heart failure; ICER, incremental cost‐effectiveness ratio; MRF, multiple risk factors; NMB, net monetary benefit; QALY, quality‐adjusted life‐year.